Other · developed by Xencor
XmAb27564 is an investigational agent administered subcutaneously every two weeks at escalating dose levels. It is being studied in psoriasis and atopic dermatitis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06005792 | Phase 1 | Psoriasis | Terminated | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Atopic DermatitisPsoriasis
Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →